June 2020 |
In response to the global outbreak of the novel coronavirus disease (COVID-19), CrossLife Technologies has developed a real-time RT-PCR test, CLT™ SARS-CoV-2 qRT-PCR Assay, intended for the qualitative detection of nucleic acid from SARSCoV-2 in bronchial fluid/wash, buccal swabs, nasal wash/aspirates, nasopharyngeal swabs, sputum, and oropharyngeal (throat)swabs from individuals with signs and symptoms of infection who are suspected of COVID-19.
Advantage as follow: 1) A unique one-step approach for RT-PCR assay. 2) Multiplexed detection of COVID-19 and positive control in one reaction. 3) Save time from multiple pipetting and reduces the risk of contamination. 4) Reduce reagent volume used to reduce the cost per test.
CLT™ SARS-CoV-2 qRT-PCR Assay provides reliable and high-quality results for clinical decision-making for the improved management of COVID-19 patients and to reduce the risk of SARS-CoV-2 (coronavirus) infection. Healthcare professionals use these tests to assess if patients are at risk of developing disease by this pathogen, which can contribute to severe upper respiratory distress, complications, and potential death.
CrossLife Tech has submitted the FDA Emergency Use Authorization and is waiting for the approval.